S
Shoichi Iriguchi
Researcher at Kyoto University
Publications - 23
Citations - 792
Shoichi Iriguchi is an academic researcher from Kyoto University. The author has contributed to research in topics: Induced pluripotent stem cell & Cytotoxic T cell. The author has an hindex of 9, co-authored 20 publications receiving 505 citations. Previous affiliations of Shoichi Iriguchi include University of Tokyo & Takeda Pharmaceutical Company.
Papers
More filters
Journal ArticleDOI
Generation of Rejuvenated Antigen-Specific T Cells by Reprogramming to Pluripotency and Redifferentiation
Toshinobu Nishimura,Shin Kaneko,Ai Kawana-Tachikawa,Yoko Tajima,Haruo Goto,Dayong Zhu,Kaori Nakayama-Hosoya,Shoichi Iriguchi,Yasushi Uemura,Takafumi Shimizu,Naoya Takayama,Daisuke Yamada,Ken Nishimura,Manami Ohtaka,Nobukazu Watanabe,Satoshi Takahashi,Aikichi Iwamoto,Haruhiko Koseki,Mahito Nakanishi,Koji Eto,Hiromitsu Nakauchi +20 more
TL;DR: This work reprogrammed clonally expanded antigen-specific CD8(+) T cells from an HIV-1-infected patient to pluripotency and found that this method can be effective for generating specific T-cells for other pathology-associated antigens.
Journal ArticleDOI
Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy.
Atsutaka Minagawa,Atsutaka Minagawa,Atsutaka Minagawa,Toshiaki Yoshikawa,Masaki Yasukawa,Akitsu Hotta,Mihoko Kunitomo,Shoichi Iriguchi,Shoichi Iriguchi,Maiko Takiguchi,Yoshiaki Kassai,Eri Imai,Yutaka Yasui,Yohei Kawai,Rong Zhang,Yasushi Uemura,Hiroyuki Miyoshi,Mahito Nakanishi,Akira Watanabe,Akira Hayashi,Kei Kawana,Kei Kawana,Tomoyuki Fujii,Tetsuya Nakatsura,Shin Kaneko,Shin Kaneko +25 more
TL;DR: It is reported that CD8αβ T cells from human T-iPSCs lose their antigen specificity through additional rearrangement of the T cell receptor (TCR) α chain gene during the CD4/CD8 double positive stage of in-vitro differentiation.
Journal ArticleDOI
A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy.
Shoichi Iriguchi,Shoichi Iriguchi,Yutaka Yasui,Yohei Kawai,Yohei Kawai,Suguru Arima,Mihoko Kunitomo,Takayuki Sato,Tatsuki Ueda,Atsutaka Minagawa,Atsutaka Minagawa,Yuta Mishima,Yuta Mishima,Nariaki Yanagawa,Nariaki Yanagawa,Yuji Baba,Yasuyuki Miyake,Yasuyuki Miyake,Kazuhide Nakayama,Maiko Takiguchi,Tokuyuki Shinohara,Tetsuya Nakatsura,Masaki Yasukawa,Masaki Yasukawa,Yoshiaki Kassai,Akira Hayashi,Shin Kaneko,Shin Kaneko +27 more
TL;DR: In this paper, the authors showed improved differentiation efficiency of T-cells from induced PSCs (iPSCs) derived from an antigen-specific cytotoxic T-cell clone, or from Tcell receptor (TCR)-transduced iPSCs, as starting materials.
Journal ArticleDOI
Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Tatsuki Ueda,Ayako Kumagai,Shoichi Iriguchi,Yutaka Yasui,Tadayo Miyasaka,Kengo Nakagoshi,Kazuki Nakane,Keigo Saito,Mari Takahashi,Aki Sasaki,Shinsuke Yoshida,Naoko Takasu,Hiroshi Seno,Yasushi Uemura,Koji Tamada,Tetsuya Nakatsura,Shin Kaneko +16 more
TL;DR: The methods for the stable, feeder‐free production of CAR‐expressing NK/ILC cells from CAR‐transduced iPSC with clinically relevant scale and materials are described, and these methods should accelerate the development of allogeneic pluripotent stem cell‐based immune cell cancer therapies.
Journal ArticleDOI
Cellular Adjuvant Properties, Direct Cytotoxicity of Re-differentiated Vα24 Invariant NKT-like Cells from Human Induced Pluripotent Stem Cells
Shuichi Kitayama,Rong Zhang,Tianyi Liu,Norihiro Ueda,Shoichi Iriguchi,Yutaka Yasui,Yohei Kawai,Minako Tatsumi,Norihito Hirai,Yasutaka Mizoro,Tatsuaki Iwama,Akira Watanabe,Mahito Nakanishi,Kiyotaka Kuzushima,Yasushi Uemura,Shin Kaneko +15 more
TL;DR: The immunological features of re-differentiated iNKT cells and their unlimited availability from induced pluripotent stem cells offer a potentially effective immunotherapy against cancer.